Quarterly ResultMay 7, 2026, 08:16 AM
Prime Medicine Q1 Net Loss $49.1M; CFO Appointed; Pipeline Progress
AI Summary
Prime Medicine reported a Q1 2026 net loss of $49.1 million, an improvement from $51.9 million in Q1 2025. The company announced pipeline progress, including being on track to file IND/CTA for PM577 and PM647 in H1 and mid-2026, respectively, with initial clinical data expected in 2027. Additionally, Svetlana Makhni was appointed as Chief Financial Officer in April 2026, and the company maintains a cash runway into 2027 with $149.2 million in cash and investments.
Key Highlights
- Svetlana Makhni appointed Chief Financial Officer in April 2026.
- On track to file IND/CTA for PM577 (Wilson Disease) in H1 2026 and PM647 (AATD) mid-2026.
- Reported Q1 2026 net loss of $49.1 million, down from $51.9 million in Q1 2025.
- Research and Development expenses decreased to $34.1 million from $40.6 million YoY.
- General and Administrative expenses increased to $17.4 million from $13.3 million YoY.
- Cash, cash equivalents, and investments totaled $149.2 million as of March 31, 2026.
- Company expects current cash to fund operations into 2027.